DOCS Stock Analysis — Doximity
Sector: Healthcare Software
AI Verdict
DOCS is cheap for the growth you're getting, but the moat's durability depends on keeping doctors engaged and competitors at bay.
Competitive Moat
Doximity operates a professional network tailored to physicians, with deep integration into hospital workflows and exclusive access to a highly specialized user base. Its defensibility comes from network effects: doctors use Doximity because their peers and referral partners are already there, making it hard for new entrants to replicate the community or data.
Summary
Doximity trades at just 14.6x next year's earnings while analysts expect 33.6% EPS growth, making it unusually cheap for a software stock.
Where It Stands
With a forward P/E of 14.6x versus the software sector median of 35x and trailing EPS growth of 33.6%, DOCS is priced well below peers despite double-digit growth.
Key Metrics
- Trailing P/E: 19.5x
- Forward P/E: 14.6x
- PEG Ratio: 0.58
- Earnings Growth: +0.3%
- Revenue Growth: +0.1%
- 52-Week High: $76.51
- 52-Week Low: $17.15
Analyst Consensus
16 Buy · 14 Hold · 0 Sell (30 analysts)
Bull Case
A forward P/E of 14.6x with 33.6% expected EPS growth means you're paying less than half the typical software multiple for rapid earnings expansion.
Bear Case
If DOCS rerates to a sector-median 35x P/E from its current 19.5x trailing P/E, the upside is capped unless growth accelerates further.
Catalyst to Watch
Watch for user engagement or new feature rollouts that could accelerate EPS growth above the current 33.6% consensus.